Yan Leyfman
Apr 29, 2025, 04:17
Yan Leyfman: Exciting Breakthrough in Relapsed/Refractory AML
Yan Leyfman, Co-founder and executive director of MedNews Week, posted on LinkedIn:
“Exciting Breakthrough in Relapsed/Refractory AML!
New interim data from the Phase 1 SENTI-202-101 trial (NCT06325748) shows promising results for SENTI-202, a first-in-class Logic Gated CAR NK cell therapy:
Key Highlights:
SENTI-202 selectively kills AML blasts and leukemia stem cells (LSCs) while sparing healthy hematopoietic stem cells (HSPCs)
No DLTs reported; SENTI-202 was well tolerated
4 of 6 patients achieved composite complete remission (cCR)
All 3 CR patients were MRD-negative
No G5 adverse events or serious SENTI-202 related toxicities
Preliminary CyTOF shows effective LSC depletion + HSPC preservation!
Next steps: Ongoing dose escalation + new data from alternative dosing schedules coming soon!
These results highlight SENTI-202’s potential to reshape outcomes for R/R AML patients.”
Read more posts featuring AML at OncoDaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 29, 2025, 04:17
Apr 29, 2025, 04:10
Apr 29, 2025, 03:29